You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股》勁方醫藥科技通過上市聆訊
阿思達克 09-01 11:08
專注於腫瘤、自體免疫和炎症性疾病領域的勁方醫藥科技上月底通過聯交所上市聆訊,預料不日將於香港掛牌,中信証券為其獨家保薦人。 初步資料顯示,勁方醫藥產品管線擁有八款候選藥品,其中五款處於臨床開發階段,包括核心產品GFH925和GFH375,前者已在中國獲商業化批准,用於治療晚期非小細胞肺癌,後者則為KRAS G12D 口服生物可利用小分子抑制劑,目前已在中國啟動針對攜帶KRAS G12D突變的晚期實體瘤患者的I/II期臨床試驗II期部分。 勁方醫藥科技循18A章申請上市,目前尚未錄得盈利,並預計於可預見未來將繼續產生淨虧損。公司預料截至今年底止全年淨虧損將增加,主要由於已確認的知識產權授權收入減少、與上市相關開支增加,及研發開支隨著研發活動的開展而增加所致。截至今年4月底止首四個月,勁方醫藥錄收入8,214.9萬元人民幣,對比去年同期未錄收入,淨虧損則達到6,662.4萬元人民幣,較上年同期的4.05億元人民幣收窄。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account